Claire Mazumdar - 10 Aug 2026 Form 4 Insider Report for Bicara Therapeutics Inc. (BCAX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: BCAX
Reported as of: 10 Aug 2026
Net transaction value: -$279,750
SEC form: 4
Accepted by SEC: 12 Aug 2026, 16:19:16 UTC
Prior SEC filing: 14 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Ryan Cohlhepp, Attorney-in-Fact

Key filing fact

Claire Mazumdar filed Form 4 for Bicara Therapeutics Inc. (BCAX) on 12 Aug 2026.

Key facts

This page summarizes Claire Mazumdar's Form 4 filing for Bicara Therapeutics Inc. (BCAX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Aug 2026, 16:19.

Change

Previous filing in this sequence was filed on 14 Jul 2026.
Current net transaction value: -$279,750.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002034671 Primary reporting owner

Mazumdar Claire

Relationship: Chief Executive Officer, Director
Address: BICARA THERAPEUTICS INC., 116 HUNTINGTON AVENUE, SUITE 703, BOSTON
Signature: /s/ Ryan Cohlhepp, Attorney-in-Fact
Signature date: 12 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCAX transaction

Common Stock

Options Exercise

Transaction value
Shares: +10,000
Change %: +2.8%
Price: $3.79^*
Shares after: 372,152
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1

BCAX transaction

Common Stock

Sale

Transaction value: $279,750
Shares: -10,000
Change %: -2.7%
Price: $27.98
Shares after: 362,152
Date: 10 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCAX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -10,000
Change %: -8.3%
Price: $0.000000^*
Shares after: 110,546
Date: 10 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $3.79
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.58 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Footnote F3

The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.